May 8, 2023
Tag: Matthew Milowsky
May 1, 2023
OncLive: Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery
December 13, 2022
Bladder cancer: what patients need to know
Each year, nearly 75,000 people are diagnosed with bladder cancer. While more common in men over age 55, bladder cancer can—and does—affect women and men of all ages. Hear from our bladder cancer specialists to learn what newly diagnosed patients and their loved ones should know about bladder cancer.
November 30, 2022
Precision Oncology News: Bladder Cancer Genomic Landscape Study Aims to Engender New Biomarker-Guided Therapies
November 14, 2022
Genetic analysis of the most common type of bladder cancer in patients with metastatic disease yields guidance on treatment options
A genomic study of more than 200 people with the most common type of bladder cancer that has spread could help guide how the cancer would respond to immunotherapy.
June 1, 2022
UNC Lineberger faculty present research at the American Society of Clinical Oncology annual meeting
UNC Lineberger members will be presenting research findings, providing commentary and leading education sessions at the American Society of Clinical Oncology’s 58th annual meeting.
November 24, 2021
WTKR: News 3 Anchor Zak Dahlheimer shares story of fighting testicular cancer
August 30, 2021
Chemotherapy plus immunotherapy before surgery is beneficial for invasive bladder cancer outcomes
Tracy Rose, MD, MPH, Matthew Milowsky, MD, and colleagues report that the regimen reduced the invasiveness of the cancer in 56% of patients in a phase II clinical trial.
August 16, 2021
Experimental drug that boosts immunotherapy shows promise in bladder cancer study
William Kim, MD, and colleagues have published findings that adding the experimental drug entinostat to an immunotherapy-like treatment substantially boosted cancer remission in laboratory models.
July 27, 2021
Patients with advanced bladder cancer could benefit from immunotherapy regardless of gene mutation status
Led by William Kim, MD, and colleagues, this research has important implications for patients who have not been offered immunotherapy because of their genetic profiles.